Late-phase trials of targeted therapies for elevated lipoprotein(a) are nearing completion, with the first readouts expected later this year.
May 28, 2026
6 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
Five biotech news updates to stay on top of today
Ahead of ASCO, all eyes on pancreatic cancer
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
A single lipoprotein(a) screening in a person’s lifetime could significantly reduce their risk for heart disease-related…
Studies show that GLP-1 receptor agonists have significant potential for treating glaucoma, diabetic retinopathy and other eye…
CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the…
ORLANDO — Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening…
In this Healio video, Christopher Lock, MD, discusses highlights in anti-amyloid therapies for Alzheimer’s disease presented at…
GLP-1 receptor agonists may help improve outcomes among women with breast cancer and chronic cardiometabolic diseases, results of…
